From the FDA Drug Label
TRINTELLIX is indicated for the treatment of major depressive disorder (MDD) in adults. The primary use of Trintellix is for the treatment of major depressive disorder (MDD) in adults 1, 1, 1.
- Key points:
- Indication: Major depressive disorder (MDD)
- Patient population: Adults
- Dosage: The recommended starting dose is 10 mg administered orally once daily without regard to meals 1.
From the Research
Trintellix (vortioxetine) is a recommended treatment for major depressive disorder in adults, with a typical starting dose of 10 mg once daily, due to its unique mechanism of action and favorable efficacy and safety profile, as demonstrated in the most recent and highest quality study 2.
Key Points
- Trintellix works by combining serotonin reuptake inhibition with modulation of serotonin receptor activity, potentially offering benefits for both mood and cognitive symptoms of depression.
- Common side effects include nausea, headache, diarrhea, dry mouth, dizziness, and sexual dysfunction, with nausea being the most common adverse event, as reported in the study 2.
- The medication has been shown to be effective in treating depressive symptoms and cognitive deficits in MDD patients, with a number needed to treat (NNT) for response of 7 and NNT for remission of 11, as calculated in the study 3.
- Trintellix may have less impact on weight gain compared to other antidepressants and may even help with cognitive function in some patients, as suggested by the study 4.
Important Considerations
- Trintellix should not be combined with MAOIs and caution is needed when taking it with other serotonergic medications due to the risk of serotonin syndrome.
- Patients should not stop taking Trintellix abruptly without medical supervision, and full antidepressant effects may take 2-4 weeks to develop, as noted in the study 5.
- The medication can be taken consistently, with or without food, and its unique psychopharmacological properties may contribute to an improved clinical outcome in MDD patient populations, as discussed in the study 2.